Business
KRTL Holding Announces KRTL Biotech Facilitates FDA Registration of SIGMACORP as a U.S. Pharmaceutical Manufacturer
KRTL Holding Announces KRTL Biotech Facilitates FDA Registration of SIGMACORP as a U.S. Pharmaceutical Manufacturer.
About this update from Krtl Holding Group, Inc
[{"type":"text","content":"\n Lakewood, CO, Dec. 05, 2024 (GLOBE NEWSWIRE) -- KRTL Holding Group, Inc. (OTC: KRTL) announces that its subsidiary, KRTL Biotech Inc., has successfully registered Industria Químico Farmaceutica SIGMA CORP. S.R.L. (SIGMACORP) with the U.S. Food and Drug Administration (FDA) as a U.S. pharmaceutical manufacturer. Acting as the U.S. Registered Agent for SIGMACORP, KRTL Biotech marks a significant step in facilitating international pharmaceutical integration and diversifying the U.S. healthcare supply chain. Strategic Milestone in Global Pharmaceutical Collaboration The FDA registration represents a pivotal achievement in KRTL Biotech’s ongoing efforts to bridge international pharmaceutical innovation with U.S. regulatory standards. This development creates opportunities to introduce cost-efficient, high-quality pharmaceutical products into the U.S. market while strengthening KRTL’s position in fostering global partnerships. Key implications include: Expanding Market Opportunities: With SIGMACORP now approved to manufacture for the U.S., the partnership is positioned to support the introduction of affordable and reliable pharmaceutical products, addressing critical market needs.Enhancing Competitive Edge: This registration underscores KRTL Biotech’s role as a leader in international pharmaceutical collaboration, enabling the company to develop long-term strategic alliances and revenue opportunities.Supporting U.S. Healthcare Resilience: By broadening the pharmaceutical supply chain, this initiative provides diverse sources for active pharmaceutical ingredients (APIs) and finished products, contributing to supply chain sustainability and innovation. A Strengthened Relationship Between the U.S. and Bolivia This milestone also signifies an important moment for U.S.-Bolivia relations in the healthcare sector. By facilitating the entry of SIGMACORP into the U.S. market, KRTL Biotech demonstrates a commitment to advancing global healthcare solutions and addressing shared challenges. COO’s Remarks “We are grateful to KRTL Biotech for their partnership and their collaboration in achieving this milestone,” said Gary Gonzales Wilstermann, COO of SIGMACORP. “Our FDA registration as a U.S. pharmaceutical manufacturer underscores our commitment to delivering high-quality, cost-effective healthcar...